Validated HPLC–PDA methodology utilized for simultaneous determination of Etoricoxib and Paracetamol in the presence of Paracetamol toxic impurities

Table 5 Determination of ETO and PCM in pharmaceutical formulation and application of the standard addition technique using the proposed HPLC method

Pharmaceutical formulation	Drug	Found% ± SD ^a	Standard addition
Pharmaceutical formulation	Drug	Found% ± SD ^a	Claimed taken (µg/mL)	Pure added (µg/mL)	Found (µg/mL)	Recovery% ^b
Intacoxia-P tablet (each tablet labeled to contain 60 mg ETO and 325 mg PCM)	ETO	99.50 ± 1.207	1.8	1.8	1.76	98.10
				3	2.98	99.46
				4.5	4.48	99.76
	Mean ± SD					99.11 ± 0.844
	%RSD					0.893
	PCM	100.22 ± 0.948	10	2	1.97	98.95
				5	4.96	99.36
				10	10.03	100.31
	Mean ± SD					99.54 ± 0.697
	%RSD					0.701

^a Application (mean ± SD) [average of three determinations of 1.8 µg/mL for ETO, and 10 µg/mL for PCM)
^b Average of three determinations

ISSN: 2661-801X